Neoplasms

Symptoms and General Pathology

All Conditions

Respiratory Tract (Lung and Bronchial) Diseases

Neoplasm Metastasis

Lung Neoplasms

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

* Group A: 70 patients with any type of lung cancer eligible for lung cancer surgery
* Group B: 30 patients with any type of lung cancer not eligible to surgery (small-cell carcinoma, squamous cell carcinoma, adenocarcinoma, large-cell carcinoma).

60 controls (group C) matched for age, gender, smoking history.

No intervention

Malcolm Kohler, Prof. MD

Felix Schmidt, RpH

Felix Schmidt, Rph

Zenobi Renato, Prof. Dr.

Martinez-Lozano Sinues Pablo, PhD

Franzen Daniel, MD

Schneiter Didier, MD

To answer the question whether a disease specific profile of breath in patients with lung cancer can be detected by an untargeted metabolomic study using exhaled breath analysis by mass spectrometry.

Mass Spectral Fingerprinting in Lung Cancer

Exhaled Breath Analysis by Secondary Electrospray Ionization - Mass Spectrometry (SESI-MS) in Patients With Lung Cancer

The primary outcome will be the lung cancer specific mass spectrometric profile of VOCs of exhaled breath analysis (markers of lung cancer in exhaled breath).

The acquired profiles of mass spectral VOCs before and after lung cancer surgery will be analysed for significant differences.

Swiss Federal Institute of Technology

University of Zurich

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Mass Spectral Fingerprinting in Lung Cancer	NCT02781857	Lung Cancer	No intervention	18 Years - 85 Years	University of Zurich
Mass Spectral Fingerprinting in Lung Cancer	NCT02781857	Lung Cancer	No intervention	18 Years - 85 Years	University of Zurich

Spots Global Cancer Trial Database for fingerprinting